Henry J.C. de Vries
YOU?
Author Swipe
View article: Environmental exposure to antibiotics drives and sustains antibiotic resistance in <i>Neisseria gonorrhoeae</i> : A modelling study
Environmental exposure to antibiotics drives and sustains antibiotic resistance in <i>Neisseria gonorrhoeae</i> : A modelling study Open
Ciprofloxacin resistance is widespread in Neisseria gonorrhoeae , despite its discontinuation as recommended treatment option in 2007. Unintentional low-level exposure to ciprofloxacin, e.g., environmental or food-borne, might provide suff…
View article: Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men Open
Supplementary material 2: HPV-Typing of AIN lesions.
View article: Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men Open
Supplementary Table S1: Proliferative T-cell responses determined by Lymphocyte Stimulation Test (LST).
View article: Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men Open
Supplementary material 1: Rationale for intradermal administration of the vaccine, the use of pegylated interferon-alpha-2b (PegIntron) as adjuvant, immune assays.
View article: Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men Open
Supplementary Table S2: T-cell responses determined by 4-day IFNγ-ELISPOT assay.
View article: Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men Open
Supplementary Table S3: Representativeness of Study Participants.
View article: Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men Open
Supplementary Figure S2: HPV16-specific T cell responses at different dose levels and time points.
View article: Estimated effect of reduced asymptomatic testing on missed Chlamydia trachomatis detections among women and heterosexual men in the Netherlands: a retrospective observational study
Estimated effect of reduced asymptomatic testing on missed Chlamydia trachomatis detections among women and heterosexual men in the Netherlands: a retrospective observational study Open
None.
View article: Lymphogranuloma venereum, an invasive and destructive sexually transmitted infection with many faces
Lymphogranuloma venereum, an invasive and destructive sexually transmitted infection with many faces Open
Lymphogranuloma venereum (LGV) is a serious, invasive, ulcerative sexually transmitted infection caused by Chlamydia trachomatis serovar L1, L2, and L3. Until 2003, we saw LGV among the general population of low- and middle-income countrie…
View article: Swab‐based anal cancer screening in men living with <scp>HIV</scp>: Projected outcomes for different screening algorithms
Swab‐based anal cancer screening in men living with <span>HIV</span>: Projected outcomes for different screening algorithms Open
Screening for and treatment of anal cancer precursor lesions, high‐grade squamous intraepithelial lesions (HSIL), can prevent anal cancer. Recent guidelines set by the International Anal Neoplasia Society recommend digital anal rectal exam…
View article: Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024
Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024 Open
BACKGROUND Doxycycline post-exposure and pre-exposure prophylaxis (doxyPEP/PrEP) to prevent sexually transmitted infections (STIs) is not part of standard practice in the Netherlands but may be used informally (without prescription). AIM W…
View article: Subpopulations with frequent healthcare barriers have increased risk of sexually transmitted infections and dropping out from HIV preexposure prophylaxis care
Subpopulations with frequent healthcare barriers have increased risk of sexually transmitted infections and dropping out from HIV preexposure prophylaxis care Open
Objective: Certain subpopulations (i.e., <25 years, transgender, sex worker, uninsured or migrant) were prioritized for inclusion in the Dutch preexposure prophylaxis (PrEP) pilot. We compared incidence of sexually transmitted infections (…
View article: Molecular Insights Into the Natural History of Anal HSIL
Molecular Insights Into the Natural History of Anal HSIL Open
Anal squamous cell carcinoma is commonly associated with human papillomavirus (HPV) infection and preceded by low‐ and high‐grade anal lesions (LSIL; HSIL). We performed a molecular comparison on paired LSIL‐ and HSIL‐lesions collected in …
View article: Renal Outcomes Over the Course of 5 Years of Oral HIV Preexposure Prophylaxis Using Tenofovir Disoproxil/Emtricitabine
Renal Outcomes Over the Course of 5 Years of Oral HIV Preexposure Prophylaxis Using Tenofovir Disoproxil/Emtricitabine Open
Daily PrEP users had a faster decline over time than event-driven PrEP users, yet eGFR declines were low and within the range of those expected in the general population. Our data support reduced kidney function monitoring in PrEP users at…
View article: Increase in<i>Neisseria gonorrhoeae</i>infections after ending COVID-19 lockdown measures in Amsterdam, the Netherlands
Increase in<i>Neisseria gonorrhoeae</i>infections after ending COVID-19 lockdown measures in Amsterdam, the Netherlands Open
Objective Various European countries noted increasing Neisseria gonorrhoeae (Ng) positivity among cis-gender women and heterosexual men. We assessed changes over time in Ng among men who exclusively have sex with men (MSM), men who exclusi…
View article: Late diagnosis of leprosy in the Netherlands: a medical-anthropological study from a patient and healthcare provider perspective
Late diagnosis of leprosy in the Netherlands: a medical-anthropological study from a patient and healthcare provider perspective Open
View article: The importance of understanding pelvic inflammatory disease as a polymicrobial infection - authors’ reply
The importance of understanding pelvic inflammatory disease as a polymicrobial infection - authors’ reply Open
View article: Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Table S1: Proliferative T-cell responses determined by Lymphocyte Stimulation Test (LST).
View article: Data from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Data from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Purpose: Anal cancer is increasing in HIV-positive men who have sex with men (MSM). Treatment options for its precursor, high-grade anal intraepithelial neoplasia (HGAIN), are suboptimal. In this phase I-II dose-finding study we assessed t…
View article: Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Figure S3: Type of T cells responding to HPV16 oncoproteins.
View article: Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Table S2: T-cell responses determined by 4-day IFNγ-ELISPOT assay.
View article: Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Table S3: Representativeness of Study Participants.
View article: Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary material 1: Rationale for intradermal administration of the vaccine, the use of pegylated interferon-alpha-2b (PegIntron) as adjuvant, immune assays.
View article: Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Figure S2: HPV16-specific T cell responses at different dose levels and time points.
View article: Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary material 1: Rationale for intradermal administration of the vaccine, the use of pegylated interferon-alpha-2b (PegIntron) as adjuvant, immune assays.
View article: Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Figure S2: HPV16-specific T cell responses at different dose levels and time points.
View article: Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Table S3: Representativeness of Study Participants.
View article: Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Figure S3: Type of T cells responding to HPV16 oncoproteins.
View article: Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Figure S1: Trial Flowchart.
View article: Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Open
Supplementary Table S2: T-cell responses determined by 4-day IFNγ-ELISPOT assay.